Navigation Links
Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
Date:2/12/2013

KANSAS CITY, Kan. and BOSTON, Mass., Feb. 12, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has appointed Don Stitzenberg as Vice President of Manufacturing and Tammy Newbold as Vice President of Chemistry, Manufacturing and Controls. Don and Tammy are both seasoned veterans in the animal health industry and are valuable additions to Aratana's growing team of experts.

Ernst Heinen , DVM, Ph.D., Head of Aratana's Drug Evaluation and Development, stated, "We believe success is contingent on assembling the strongest possible team with proven expertise in all aspects of clinical and commercial drug development. For this reason, we are very pleased to welcome Don and Tammy to Aratana, each of whom are proven experts in establishing and executing quality development and manufacturing programs for animal health drugs."

Donald Stitzenberg
Prior to joining Aratana, Mr. Stitzenberg founded Carnegie Business Associates, an international supply chain consulting company, specializing in the pharmaceutical, chemical and cosmetics industries. He spent 33 years in executive positions at Merck and Co., Inc. in marketing, research, planning and manufacturing. He was Executive Director of Planning for Merck where he led the formation of Merck AgVet, Merck's Animal Health Division. Additionally, he negotiated the formation of Merial Inc., a global animal health joint venture with Rhone Merieux (now Sanofi).

Mr. Stitzenberg holds a BS in mathematics from Carnegie Mellon University where he is a Life Member of the Carnegie Mellon Board of Trustees. He also holds an MBA and an LLB and is a Member of the New Jersey Bar Association.

Tammy Newbold
Prior to joining Aratana, Ms. Newbold founded Ceris Consulting, which provides Chemistry, Manufacturing and Controls guidance to animal health companies seeking FDA approval of products. Ms. Newbold led the Worldwide Regulatory Chemistry, Manufacturing and Controls group at Merial, Inc. Her team identified worldwide regulatory requirements to define CMC for product development and also prepared worldwide pharmaceutical regulatory dossiers. She was an Associate Manager of Regulatory Affairs at Merck & Co., Inc. where she helped define worldwide CMC regulations for animal health products. Ms. Newbold served as a Process Development Scientist at Bausch & Lomb where she was in charge of manufacturing processes and facilities.  

Ms. Newbold earned her B.S. Degree in Biochemistry from the State University of New York at Stonybrook in 1986.

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals). Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market. For more information, please visit www.aratanatherapeutics.com.

For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm , Ph.D./ Andrew Mielach
jdrumm@tiberend.com; (212) 375-2664
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Nile Therapeutics Reports 2011 Third Quarter Financial Results
5. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
6. Fate Therapeutics Strengthens Its iPSC Platform
7. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):